MyFinsight
Home
Blog
About
Contact
Download
Download image
Cash and cash
equivalents
$213,768K
Marketable securities
$71,262K
Accounts receivable, net
$9,897K
Prepaid expenses and
other current assets
$7,846K
Research and development
tax credit...
$7,430K
Inventory
$4,002K
Total current assets
$314,205K
Right of use assets
$9,421K
Property and equipment,
net
$2,841K
Other assets
$2,450K
Total assets
$328,917K
Accumulated deficit
-$786,181K
Accumulated other
comprehensive loss
-$7,116K
Total liabilities and
stockholders' deficit
$328,917K
Total stockholders'
deficit
-$19,652K
Additional paid-in capital
$773,594K
Common stock, 0.001 par
value 100,000,000...
$51K
Total liabilities
$348,569K
Convertible notes
$139,401K
Royalty obligation - net
of current portion
$116,583K
Total current
liabilities
$60,817K
Deferred revenue - net of
current portion
$21,357K
Lease liability - net
of current portion
$10,411K
Accrued expenses and
other current...
$34,022K
Royalty obligation -
current portion
$16,226K
Accounts payable
$8,045K
Lease liability -
current portion
$1,691K
Deferred revenue -
current portion
$833K
Back
Back
Balance Sheet
KalVista Pharmaceuticals, Inc. (KALV)
KalVista Pharmaceuticals, Inc. (KALV)
source: myfinsight.com